DGIdb - INFLIXIMAB Drug Record

INFLIXIMAB chembl:CHEMBL1201581 ApprovedImmunotherapy

Alternate Names:

INFLIXIMAB
ABP 710
BOW015
REMICADE
REMSIMA
NI-071
INFLECTRA
TA-650
CA2
CA2 ????
IG GAMMA-1 CHAIN C REGION
rxcui:191831
drugbank:00065
chemidplus:170277-31-3
chembl:CHEMBL1201581

Drug Info:

FDA Approval	approved
Drug Class	monoclonal antibody
Drug Indications	antiinflammatory agent,DMARD
Drug Class	immunosuppressive agents
Year of Approval	1998

(3 More Sources)

Publications:

Duftner et al., 2006, Preferential type 1 chemokine receptors and cytokine production of CD28- T cells in ankylosing spondylitis., Ann. Rheum. Dis.
Mimura, 2007, [Selection of one of the TNF blockers; infliximab and etanercept]., Nippon Rinsho
Magro et al., 2005, Reactive hepatitis in a patient with Crohn's disease successfully treated with infliximab: does tumor necrosis factor alpha play a role in reactive hepatitis?, Inflamm. Bowel Dis.
Sapienza et al., 2004, Treatment of pyoderma gangrenosum with infliximab in Crohn's disease., Dig. Dis. Sci.
Shen et al., 2005, Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept., Aliment. Pharmacol. Ther.
Braun et al., 2005, Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept., Arthritis Rheum.
Mori et al., 2006, Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody., Mod Rheumatol
Maini et al., 2002, How does infliximab work in rheumatoid arthritis?, Arthritis Res.
Popa et al., 2005, Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy., Cytokine
Tobin et al., 2005, TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis., BioDrugs
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Danese et al., 2006, TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease., J. Immunol.
Song GG et al., 2015, Association between TNF-α (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-α blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis., Pharmacogenomics
Swierkot J et al., 2015, Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis., Joint Bone Spine
Tong Q et al., 2013, Association of TNF-α polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis., Pharmacogenomics
Tong Q et al., 2012, TNF-α -857 and -1031 polymorphisms predict good therapeutic response to TNF-α blockers in Chinese Han patients with ankylosing spondylitis., Pharmacogenomics
Lacruz-Guzmán D et al., 2013, Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis., Eur J Clin Pharmacol
Zeng Z et al., 2013, Association between tumor necrosis factor-α (TNF-α) promoter -308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis., Mod Rheumatol
Daïen CI et al., 2012, TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis., Joint Bone Spine
O'Rielly DD et al., 2009, TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis., Pharmacogenomics J
Maxwell JR et al., 2008, Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis., Hum Mol Genet
Marotte H et al., 2008, Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor., Arthritis Rheum
Guis S et al., 2007, Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis., Arthritis Rheum
Miceli-Richard C et al., 2008, A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis., Ann Rheum Dis
Cuchacovich M et al., 2006, Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis., Scand J Rheumatol
Lee YH et al., 2006, Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis., Rheumatol Int
Seitz M et al., 2007, The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients., Rheumatology (Oxford)
Kang et al., 2005, The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis., Rheumatology (Oxford)
Mugnier B et al., 2003, Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis., Arthritis Rheum
Louis E et al., 2002, A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism., Scand J Gastroenterol
Mendrinou E et al., 2017, FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors., Pharmacogenomics J
Dávila-Fajardo CL et al., 2015, FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis., Pharmacogenomics
Montes A et al., 2014, Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis., Pharmacogenet Genomics
Julià M et al., 2013, The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study., JAMA Dermatol
Morales-Lara MJ et al., 2012, Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis., Joint Bone Spine
Netea et al., 2003, Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression., Arthritis Rheum.
Ovejero-Benito MC et al., 2018, Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis., Pharmacogenomics
Canet LM et al., 2015, Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: a multicenter study., Pharmacogenet Genomics
González-Lara L et al., 2015, The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in Psoriasis patients., Arch Dermatol Res
Rooryck C et al., 2008, Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy., Clin Exp Rheumatol
Julià A et al., 2014, PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis., Pharmacogenomics
Julià A et al., 2015, Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis., Pharmacogenomics J
Acosta-Colman I et al., 2013, GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis., Pharmacogenomics
Pappas DA et al., 2013, Association of rheumatoid arthritis risk alleles with response to anti-TNF biologics: results from the CORRONA registry and meta-analysis., Inflammation
Miheller et al., 2005, [Improvement of bone metabolism after infliximab therapy in Crohn's disease]., Orv Hetil
Montes A et al., 2015, FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors., Pharmacogenomics
Tsukahara S et al., 2008, A polymorphism in the gene encoding the Fcgamma IIIA receptor is a possible genetic marker to predict the primary response to infliximab in Japanese patients with rheumatoid arthritis., Ann Rheum Dis
Iwaszko M et al., 2016, Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment., Joint Bone Spine
Iwaszko M et al., 2015, Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy., Clin Exp Immunol
Dávila-Fajardo CL et al., 2014, Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome., Pharmacogenet Genomics
Cui J et al., 2010, Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy., Arthritis Rheum

INFLIXIMAB SLCO1C1

Interaction Score: 6.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25493569 25403996 23651021

Sources:
PharmGKB
INFLIXIMAB IVL

Interaction Score: 3.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29192552

Sources:
PharmGKB
INFLIXIMAB CCL3

Interaction Score: 3.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16219708

Sources:
NCI
INFLIXIMAB TNFRSF1B

Interaction Score: 2.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25850964 25537528 22129793 18565259

Sources:
PharmGKB
INFLIXIMAB FCGR2A

Interaction Score: 2.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27044681 25823785 24667440 24048425

Sources:
PharmGKB
INFLIXIMAB TRAF1

Interaction Score: 2.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23007924

Sources:
PharmGKB
INFLIXIMAB ATP5F1E

Interaction Score: 1.55

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26307125

Sources:
PharmGKB
INFLIXIMAB KLRD1

Interaction Score: 1.55

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26453102

Sources:
PharmGKB
INFLIXIMAB TNFRSF1A

Interaction Score: 1.55

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22480748

Sources:
PharmGKB
INFLIXIMAB TNF

Interaction Score: 1.55

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name infliximab ,Remicade

Novel drug target Established target

Direct Interaction yes

PMIDs:
17642244 15674127 15481318 15691299 16052578 16622728 12110154 15804598 15691217 11752352 16456024 26244882 25311255 24192118 23057546 22960943 22760475 22129793 19365401 18713756 18438841 18050183 17673491 17343250 16909270 16720636 15695296 12847678 12190096

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD
INFLIXIMAB IL12B

Interaction Score: 1.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29192552

Sources:
PharmGKB
INFLIXIMAB PTPRC

Interaction Score: 0.77

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23007924 20309874

Sources:
PharmGKB
INFLIXIMAB HLA-E

Interaction Score: 0.77

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
INFLIXIMAB CCL17

Interaction Score: 0.77

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16219708

Sources:
NCI
INFLIXIMAB FCGR3A

Interaction Score: 0.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27044681 25823782 24048425 19005160

Sources:
PharmGKB
INFLIXIMAB TLR4

Interaction Score: 0.56

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12847679

Sources:
NCI
INFLIXIMAB BGLAP

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16130441

Sources:
NCI
INFLIXIMAB IL6

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24253594

Sources:
PharmGKB
INFLIXIMAB IL1B

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22960943

Sources:
PharmGKB
INFLIXIMAB HLA-DRB1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB

TEND: INFLIXIMAB
- Version: 01-August-2011
Alternate Names:

INFLIXIMAB Primary Drug Name

Drug Info:

Year of Approval 1998

Drug Class immunosuppressive agents

Publications:
TdgClinicalTrial: INFLIXIMAB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antiinflammatory agent,DMARD

Drug Class monoclonal antibody

FDA Approval approved

Publications:

NCI: INFLIXIMAB

Version: 14-September-2017

Alternate Names:

C1789 NCI drug code

Drug Info:

Publications:

Duftner et al., 2006, Preferential type 1 chemokine receptors and cytokine production of CD28- T cells in ankylosing spondylitis., Ann. Rheum. Dis.

Miheller et al., 2005, [Improvement of bone metabolism after infliximab therapy in Crohn's disease]., Orv Hetil

Netea et al., 2003, Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression., Arthritis Rheum.

PharmGKB: infliximab

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Morales-Lara MJ et al., 2012, Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis., Joint Bone Spine

Cui J et al., 2010, Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy., Arthritis Rheum

Pappas DA et al., 2013, Association of rheumatoid arthritis risk alleles with response to anti-TNF biologics: results from the CORRONA registry and meta-analysis., Inflammation

TTD: Infliximab
- Version: 2020.06.01
Alternate Names:

D0PG5G TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1201581
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1201581
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Trial Name	infliximab ,Remicade
Novel drug target	Established target
Direct Interaction	yes

INFLIXIMAB Drug Record

INFLIXIMAB chembl:CHEMBL1201581 ApprovedImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25493569 25403996 23651021

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29192552

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16219708

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25850964 25537528 22129793 18565259

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27044681 25823785 24667440 24048425

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23007924

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26307125

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26453102

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22480748

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name infliximab ,Remicade Novel drug target Established target Direct Interaction yes

PMIDs: 17642244 15674127 15481318 15691299 16052578 16622728 12110154 15804598 15691217 11752352 16456024 26244882 25311255 24192118 23057546 22960943 22760475 22129793 19365401 18713756 18438841 18050183 17673491 17343250 16909270 16720636 15695296 12847678 12190096

Sources: TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29192552

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23007924 20309874

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16219708

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27044681 25823782 24048425 19005160

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12847679

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16130441

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24253594

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22960943

Interaction Types & Directionality:

n/a

PMIDs:
25493569 25403996 23651021

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29192552

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16219708

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
25850964 25537528 22129793 18565259

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27044681 25823785 24667440 24048425

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23007924

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26307125

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26453102

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22480748

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name infliximab ,Remicade

Novel drug target Established target

Direct Interaction yes

PMIDs:
17642244 15674127 15481318 15691299 16052578 16622728 12110154 15804598 15691217 11752352 16456024 26244882 25311255 24192118 23057546 22960943 22760475 22129793 19365401 18713756 18438841 18050183 17673491 17343250 16909270 16720636 15695296 12847678 12190096

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
29192552

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23007924 20309874

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16219708

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
27044681 25823782 24048425 19005160

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12847679

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16130441

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
24253594

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22960943

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Alternate Names:

INFLIXIMAB Primary Drug Name

Drug Info:

Year of Approval 1998

Drug Class immunosuppressive agents

Drug Info:

Drug Indications antiinflammatory agent,DMARD

Drug Class monoclonal antibody

FDA Approval approved

Alternate Names:

C1789 NCI drug code

Alternate Names:

D0PG5G TTD Drug ID